PE-Backed Synteract Acquires Harrison Clinical Research
December 21, 2012
Share:
Synteract, a San Diego-based contract research organization (CRO) and portfolio company of Gryphon Investors, has agreed to acquire Harrison Clinical Research, a multinational CRO based in Munich, Germany. CROs help support biotech, medical device and pharmaceutical companies in all phases of clinical development. Synteract plans to combine operations to become a global service provider. The acquisition will bring in operations in Europe, Israel and South America, including Harrison's clinical in-patient unit in Germany and a clinical research training center in Belgium. Alongside minority investors Northstar Capital and Ticonderoga Capital, Grypon acquired Synteract from Celerity Partners in 2008. Fairmount Partners represented Synteract in a focused acquisition search and on the transaction with Harrison.
